Symbicort NDA On-Track, Exanta Decision Set For Second-Half – AstraZeneca
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca will submit additional data for Symbicort inhalation delivery device. Hold-up comes in wake of setbacks for Iressa, Exanta and Crestor